uniQure NV
uniQure NV (QURE) Wheel Strategy
QURE wheel strategy scan found 39 cash-secured put setups on the previous trading day. Probability of expiring worthless is above 50%. Annualized returns reach up to 186.6%.
Read more
Running a QURE wheel strategy lets you generate consistent premium income on uniQure NV while setting your own entry and exit prices on the underlying. uniQure NV's wheel combines cash-secured puts and covered calls into a repeatable cycle: sell puts at strikes where you'd be happy to own QURE, and if assigned, sell calls at strikes where you'd be happy to sell. Use our scanner to find the best QURE wheel strategy setups in real time.
The wheel works best on liquid, high-quality names with stable fundamentals and active options markets — exactly the profile many large-cap leaders fit. The mechanics are simple: sell a cash-secured put on QURE, collect premium, and either keep the premium if it expires worthless or take assignment at a discount to current price. Once assigned, sell covered calls against the shares to keep collecting premium until they're called away. Choosing the right strikes, expirations, and IV environment is what separates a profitable QURE wheel from a losing one.
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis.
uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
The difference between a wheel that compounds and one that bleeds comes down to strike selection, IV timing, and discipline on assignment. Our scanner handles the heavy lifting: it ranks every leg of the QURE wheel strategy by delta, premium yield, IV rank, and days to expiration, so you can deploy capital where the math works. Build your QURE wheel strategy on data, not gut feel — and let the options wheel do what it does best: pay you to wait.
| Oct 16, 2026 | 36.00 | $3.40 | $4.05 | -0.36 | 22 | 67% | 50.5% | 186.6% | 252 |
| Oct 16, 2026 | 35.00 | $2.85 | $3.68 | -0.33 | 22 | 67% | 53.8% | 174.2% | 813 |
| Oct 16, 2026 | 34.00 | $2.70 | $3.25 | -0.30 | 22 | 67% | 57.1% | 158.6% | 7 |
| Oct 16, 2026 | 33.00 | $2.35 | $2.93 | -0.28 | 22 | 67% | 60.4% | 147.1% | 290 |
| Oct 16, 2026 | 32.00 | $2.15 | $2.73 | -0.25 | 22 | 67% | 63.8% | 141.3% | 14 |
| Oct 16, 2026 | 31.00 | $1.65 | $2.38 | -0.23 | 22 | 67% | 67.2% | 127.1% | 432 |
| Oct 16, 2026 | 29.00 | $1.00 | $1.85 | -0.18 | 22 | 67% | 73.8% | 105.8% | 56 |
| Oct 16, 2026 | 30.00 | $1.30 | $1.65 | -0.19 | 22 | 67% | 70.5% | 91.3% | 2,645 |
| Oct 16, 2026 | 28.00 | $0.85 | $1.45 | -0.16 | 22 | 67% | 77.0% | 85.9% | 47 |
| Nov 20, 2026 | 32.00 | $3.40 | $4.15 | -0.27 | 57 | 67% | 52.0% | 83.0% | 6 |
As of September 25, 2026
Run the Wheel on QURE With Confidence
Find the best QURE wheel strategy setups across strikes and expirations, plan ahead with at-strike values, and keep your covered calls and puts on track.
Start your 14-day free trial→